�Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced that enrollment
into its two Phase 3 pivotal studies evaluating Viprinex(TM) (ancrod) for
the discourse of sharp ischemic stroke has reached the stratum of patients
necessary to conduct a planned meanwhile analysis across the deuce studies. NTI
is currently studying whether Viprinex is safe and effective for treating
acute ischemic virgule when
